FY2026 · ended Jun 30, 2026 · Revenue $1.52B, +17.1% YoY · Filed Aug 26, 2026
Phibro Animal Health Corporation (PAHC) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2026, which ended Jun 30, 2026, it reported revenue of $1.5 billion and net income of $99.7 million. Free cash flow was $9.9 million. As of Sep 30, 2026 it held $83.1 million in cash and investments and $665.1 million in total debt.
Revenue (TTM)
$1.54B
+10.1% vs year-ago TTM
Net income (TTM)
$102.71M
+51.5% vs year-ago TTM
Operating cash flow (TTM)
$85.73M
+11.6% vs year-ago TTM
Free cash flow (TTM)
$21.67M
-36.8% vs year-ago TTM
EPS (TTM)
$2.51
+50.6% vs year-ago TTM
Dividend per share (TTM)
$0.48
+0.0% vs year-ago TTM
Shares outstanding
30.46M
Net cash
$-582.00M
as of Sep 30, 2026
Operating margin
12.5%
FY 2027
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PAHC (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Teaneck, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1069899
- Former names
- PHILIPP BROTHERS CHEMICALS INC (until May 14, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jun 30, 2026 |
FY 2025 Jun 30, 2025 |
FY 2024 Jun 30, 2024 |
FY 2023 Jun 30, 2023 |
FY 2022 Jun 30, 2022 |
|---|---|---|---|---|---|
| Revenue | $1.5B | $1.3B | $1.0B | $977.9M | $942.3M |
| Operating income | $194.4M | $110.5M | $53.3M | $71.8M | $79.0M |
| Net income | $99.7M | $48.3M | $2.4M | $32.6M | $49.2M |
| Diluted EPS | $2.43 | $1.19 | $0.06 | $0.81 | $1.21 |
| Operating cash flow | $69.0M | $80.1M | $87.6M | $13.3M | $31.6M |
| Free cash flow | $9.9M | $41.8M | $46.4M | -$38.5M | -$5.4M |
| Total assets | $1.5B | $1.4B | $982.2M | $971.4M | $931.7M |
| Total liabilities | $1.1B | $1.1B | $725.5M | $688.9M | $669.3M |
| Stockholders' equity | $385.5M | $285.7M | $256.6M | $282.5M | $262.4M |
| Cash and investments | $82.0M | $77.0M | $114.6M | $81.3M | $91.2M |
| Total debt | $56.0M | $42.9M | $349.5M | $369.0M | $37.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Shareholder vote results
|
Nov 4, 2026 | Nov 3, 2026 |
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Nov 3, 2026 | Nov 3, 2026 |
| ARS | Annual report to shareholders | Sep 18, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 26, 2026 | Aug 26, 2026 |
| 10-K | Annual report | Aug 26, 2026 | Jun 30, 2026 |
All 774 Phibro Animal Health Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.